SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL) explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL) trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat brain lymphoma
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people whose central nervous system lymphoma has come back or not responded to treatment. About 26 adults with this rare cancer will receive the drug combination. The main goal is to …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising cocktail targets brain cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 people with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this mix can stop the cancer from growing for at least a yea…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA (SCNSL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC